XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues:        
Total revenues $ 29,222 $ 31,126 $ 55,712 $ 63,574
Costs and expenses:        
Cost of sales 10,677 8,889 18,463 20,066
Research and development expenses 387 798 825 1,531
Selling, general and administrative expenses 16,960 18,385 38,935 36,909
Amortization of intangible assets 9,233 6,671 18,465 12,302
Restructuring charges 0 0 289 720
Total costs and expenses 37,257 34,743 76,977 71,528
Loss from operations (8,035) (3,617) (21,265) (7,954)
Other (expense) income:        
Loss on Assertio Therapeutics divestiture (8,174) 0 (8,174) 0
Interest expense (768) (758) (1,533) (1,515)
Interest income 675 842 1,395 1,554
Other gain (loss) 6 8 (15) 12
Total other (expense) income (8,261) 92 (8,327) 51
Net loss before income taxes (16,296) (3,525) (29,592) (7,903)
Income tax expense (56) (149) (301) (281)
Net loss and comprehensive loss $ (16,352) $ (3,674) $ (29,893) $ (8,184)
Basic net loss per share (in dollars per share) $ (0.17) $ (0.04) $ (0.31) $ (0.09)
Diluted net loss per share (in dollars per share) $ (0.17) $ (0.04) $ (0.31) $ (0.09)
Shares used in computing basic net loss per share (in shares) 95,970 95,240 95,824 95,110
Shares used in computing diluted net loss per share (in shares) 95,970 95,240 95,824 95,110
Product sales, net        
Revenues:        
Total revenues $ 28,822 $ 30,695 $ 54,818 $ 62,557
Royalty revenue        
Revenues:        
Total revenues $ 400 $ 431 $ 894 $ 1,017